Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD34+ enriched cell fraction
- Development stage
- Unknown
- Lead developer
- CellProthera
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
Autologous CD34+ enriched cell fraction is an investigational cell therapy consisting of hematopoietic stem and progenitor cells (HSPCs) harvested from a patient's own peripheral blood or bone marrow. Developed by the Unidade Local de Saúde de Coimbra (ULS Coimbra), this therapy is specifically being evaluated for the treatment of acute ischemic stroke. The process involves mobilizing CD34+ cells using granulocyte colony-stimulating factor (G-CSF), followed by enrichment via immunomagnetic selection. The enriched cell fraction is then administered intra-arterially into the brain's ischemic territory. The therapeutic effect is mediated through paracrine mechanisms, where the cells secrete angiogenic and neurotrophic factors—such as vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1)—that promote neovascularization, reduce neuronal apoptosis, and enhance endogenous repair processes in the ischemic penumbra.
- Other names
- autologous CD34+ cellsCD34+ enriched cell fraction
Beyond the preview
Go deeper on autologous CD34+ enriched cell fraction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD34+ enriched cell fraction.